Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 595
- Registration Number
- NCT00406640
Dichotic Listening as a Predictor of Medication Response in Depression
- Conditions
- Interventions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00404755
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism
- Conditions
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 16
- Registration Number
- NCT00397059
- Locations
- 🇩🇰
Clinical Pharmacology, University of Southern Denmark, Odense, Denmark
Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 80
- Registration Number
- NCT00386841
- Locations
- 🇩🇰
Psychiatric Department of Rigshospitalet, Blegdamsvej 9, Copenhagen OE, Denmark
Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2008-01-07
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 580
- Registration Number
- NCT00384436
- Locations
- 🇺🇸
For information regarding investigative sites, contact Forest Professional Affairs, St Louis, Missouri, United States
Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 118
- Registration Number
- NCT00375843
- Locations
- 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Harvard/MGH, Boston, Massachusetts, United States
Imaging Predictors of Treatment Response in Depression
- Conditions
- Interventions
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Emory University
- Target Recruit Count
- 82
- Registration Number
- NCT00367341
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Identifying Factors That Predict Antidepressant Treatment Response
- Conditions
- Interventions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Emory University
- Target Recruit Count
- 344
- Registration Number
- NCT00360399
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Emory University Mood and Anxiety Disorders Program, Atlanta, Georgia, United States
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT00352885
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.